Krystal Biotech (KRYS)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$6.60 (-3.39%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Krystal Biotech (KRYS)
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Key Insights

Critical company metrics and information
  • Share Price

    $190.00
  • Market Cap

    $5.46 Billion
  • Total Outstanding Shares

    28.76 Million Shares
  • Total Employees

    229
  • Dividend

    No dividend
  • IPO Date

    September 20, 2017
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.krystalbio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$729000.00
Exchange Gains/Losses$4000.00
Net Cash Flow$725000.00
Net Cash Flow From Operating Activities$63.34 Million
Net Cash Flow From Investing Activities$-89.82 Million
Net Cash Flow From Investing Activities, Continuing$-89.82 Million
Net Cash Flow From Financing Activities$27.20 Million
Net Cash Flow From Operating Activities, Continuing$63.34 Million
Net Cash Flow From Financing Activities, Continuing$27.20 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Parent$52.37 Million
Research and Development$51.42 Million
Income Tax Expense/Benefit$5.03 Million
Operating Expenses$214.06 Million
Income/Loss From Continuing Operations After Tax$52.37 Million
Diluted Earnings Per Share$1.78
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Costs And Expenses$184.12 Million
Benefits Costs and Expenses$184.12 Million
Net Income/Loss Available To Common Stockholders, Basic$52.37 Million
Operating Income/Loss$27.45 Million
Other Operating Expenses$153.88 Million
Basic Average Shares$85.95 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Basic Earnings Per Share$1.84
Income/Loss From Continuing Operations Before Tax$57.40 Million
Net Income/Loss$52.37 Million
Preferred Stock Dividends And Other Adjustments$0.00
Revenues$241.52 Million
Diluted Average Shares$89.20 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Noncontrolling Interest$0.00
Inventory$18.58 Million
Other Current Liabilities$83.95 Million
Equity Attributable To Parent$885.85 Million
Current Liabilities$89.53 Million
Cash$588.30 Million
Current Assets$713.16 Million
Liabilities$96.47 Million
Other Non-current Assets$112.56 Million
Other Current Assets$106.28 Million
Accounts Payable$5.58 Million
Noncurrent Assets$269.15 Million
Noncurrent Liabilities$6.95 Million
Fixed Assets$156.59 Million
Liabilities And Equity$982.32 Million
Equity$885.85 Million
Assets$982.32 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.